Skip to main content
Top
Published in: Cancer Immunology, Immunotherapy 11/2012

01-11-2012 | Original article

Combining synthetic carbohydrate vaccines with cancer cell glycoengineering for effective cancer immunotherapy

Authors: Lei Qiu, Xi Gong, Qianli Wang, Jie Li, Honggang Hu, Qiuye Wu, Junping Zhang, Zhongwu Guo

Published in: Cancer Immunology, Immunotherapy | Issue 11/2012

Login to get access

Abstract

Tumor-associated carbohydrate antigens (TACAs) are useful targets for the development of cancer vaccines or immunotherapies. However, a major obstacle in this application of TACAs is their poor immunogenicity. To overcome the problem, a new immunotherapeutic strategy combining synthetic vaccines made of artificial TACA derivatives and metabolic glycoengineering of cancer cells to express the artificial TACA derivatives was explored. Using a murine leukemia model FBL3 with GM3 antigen as the target, it was shown that artificial GM3 N-phenylacetyl derivative (GM3NPhAc) elicited robust antigen-specific T cell-dependent immunity and that N-phenylacetyl-d-mannosamine (ManNPhAc) as the biosynthetic precursor of GM3NPhAc selectively glycoengineered cancer cells to express GM3NPhAc both in vitro and in vivo. It was also demonstrated that GM3NPhAc-specific antisera and antibodies mediated strong cytotoxicity to ManNPhAc-treated FBL3 cell. Furthermore, vaccination with a conjugate vaccine made of GM3NPhAc followed by ManNPhAc treatment could significantly suppress tumor growth and prolong the survival of tumor-bearing mouse. These results have proved the feasibility of the new cancer immunotherapeutic strategy, as well as its efficacy to cure cancer, which is of general significance.
Literature
1.
go back to reference Dube DH, Bertozzi CR (2005) Glycans in cancer and inflammation-potential for therapeutics and diagnostics. Nat Rev Drug Discov 4:477–488PubMedCrossRef Dube DH, Bertozzi CR (2005) Glycans in cancer and inflammation-potential for therapeutics and diagnostics. Nat Rev Drug Discov 4:477–488PubMedCrossRef
2.
go back to reference Wang Q, Guo Z (2009) Recent development in carbohydrate-based cancer vaccines. Curr Opin Chem Biol 13:608–617PubMedCrossRef Wang Q, Guo Z (2009) Recent development in carbohydrate-based cancer vaccines. Curr Opin Chem Biol 13:608–617PubMedCrossRef
3.
go back to reference Livingston PO (1995) Approaches to augmenting the immunogenicity of melanoma gangliosides: from the whole melanoma cells to ganglioside-KLH conjugate vaccines. Immunol Rev 145:147–156PubMedCrossRef Livingston PO (1995) Approaches to augmenting the immunogenicity of melanoma gangliosides: from the whole melanoma cells to ganglioside-KLH conjugate vaccines. Immunol Rev 145:147–156PubMedCrossRef
4.
go back to reference Danishefsky SJ, Allen JR (2000) From the laboratory to the clinic: a retrospective on fully synthetic carbohydrate-based anticancer vaccines. Angew Chem Int Ed 39:837–863CrossRef Danishefsky SJ, Allen JR (2000) From the laboratory to the clinic: a retrospective on fully synthetic carbohydrate-based anticancer vaccines. Angew Chem Int Ed 39:837–863CrossRef
5.
go back to reference Buskas T, Ingale S, Boons GJ (2005) Towards a fully synthetic carbohydrate-based anticancer vaccine: synthesis and immunological evaluation of a lipidated glycopeptide containing the tumor-associated Tn antigen. Angew Chem Int Ed 44:5985–5988CrossRef Buskas T, Ingale S, Boons GJ (2005) Towards a fully synthetic carbohydrate-based anticancer vaccine: synthesis and immunological evaluation of a lipidated glycopeptide containing the tumor-associated Tn antigen. Angew Chem Int Ed 44:5985–5988CrossRef
6.
go back to reference Renaudet O, BenMohamed L, Dasgupta G, Bettahi I, Dumy P (2008) Towards a self-adjuvanting multivalent B and T cell epitope containing synthetic glycolipopeptide cancer vaccine. ChemMedChem 3:737–741PubMedCrossRef Renaudet O, BenMohamed L, Dasgupta G, Bettahi I, Dumy P (2008) Towards a self-adjuvanting multivalent B and T cell epitope containing synthetic glycolipopeptide cancer vaccine. ChemMedChem 3:737–741PubMedCrossRef
7.
go back to reference Ingale S, Wolfert MA, Buskas T, Boons GJ (2009) Increasing the antigenicity of synthetic tumor-associated carbohydrate antigens by targeting Toll-like receptors. ChemBioChem 10:455–463PubMedCrossRef Ingale S, Wolfert MA, Buskas T, Boons GJ (2009) Increasing the antigenicity of synthetic tumor-associated carbohydrate antigens by targeting Toll-like receptors. ChemBioChem 10:455–463PubMedCrossRef
8.
go back to reference Wilkinson BL, Day S, Malins LR, Apostolopoulos V, Payne RJ (2011) Self-adjuvanting multicomponent cancer vaccine candidates combining per-glycosylated MUC1 Glycopeptides and the toll-like receptor 2 agonist Pam3CysSer. Angew Chem Int Ed 50:1635–1639CrossRef Wilkinson BL, Day S, Malins LR, Apostolopoulos V, Payne RJ (2011) Self-adjuvanting multicomponent cancer vaccine candidates combining per-glycosylated MUC1 Glycopeptides and the toll-like receptor 2 agonist Pam3CysSer. Angew Chem Int Ed 50:1635–1639CrossRef
9.
go back to reference Tang S, Wang Q, Guo Z (2010) Synthesis of a monophosphoryl derivative of Escherichia coli lipid A and its efficient coupling to a tumor-associated carbohydrate antigen. Chem Eur J 16:1319–1325PubMedCrossRef Tang S, Wang Q, Guo Z (2010) Synthesis of a monophosphoryl derivative of Escherichia coli lipid A and its efficient coupling to a tumor-associated carbohydrate antigen. Chem Eur J 16:1319–1325PubMedCrossRef
10.
go back to reference Wang Q, Zhou Z, Tang S, Guo Z (2012) Carbohydrate-monophosphoryl lipid A conjugates are fully synthetic self-adjuvanting cancer vaccines eliciting robust immune responses in the mouse. ACS Chem Biol 7. doi:10.1021/cb200358r Wang Q, Zhou Z, Tang S, Guo Z (2012) Carbohydrate-monophosphoryl lipid A conjugates are fully synthetic self-adjuvanting cancer vaccines eliciting robust immune responses in the mouse. ACS Chem Biol 7. doi:10.​1021/​cb200358r
11.
go back to reference Wang Q, Guo Z (2009) Synthesis of a monophosphoryl lipid A derivative and its coupling to a tumor-associated carbohydrate antigen for cancer vaccine development. Chem Commun 5536–5537 Wang Q, Guo Z (2009) Synthesis of a monophosphoryl lipid A derivative and its coupling to a tumor-associated carbohydrate antigen for cancer vaccine development. Chem Commun 5536–5537
12.
go back to reference Chapman PB, Morrissey DM, Panageas KS, Hamilton WB, Zhan C, Destro AN, Williams L, Israel RJ, Livingston PO (2000) Induction of antibodies against GM2 ganglioside by immunizing melanoma patients using GM2-keyhole limpet hemocyanin + QS21 vaccine: a dose-response study. Clin Cancer Res 6:874–879PubMed Chapman PB, Morrissey DM, Panageas KS, Hamilton WB, Zhan C, Destro AN, Williams L, Israel RJ, Livingston PO (2000) Induction of antibodies against GM2 ganglioside by immunizing melanoma patients using GM2-keyhole limpet hemocyanin + QS21 vaccine: a dose-response study. Clin Cancer Res 6:874–879PubMed
13.
go back to reference Holmberg LA, Sandmaier BM (2004) Vaccination with Theratope (STn-KLH) as treatment for breast cancer. Expert Rev Vaccines 3:655–663PubMedCrossRef Holmberg LA, Sandmaier BM (2004) Vaccination with Theratope (STn-KLH) as treatment for breast cancer. Expert Rev Vaccines 3:655–663PubMedCrossRef
14.
go back to reference Franco A (2008) Glycoconjugates as vaccines for cancer immunotherapy: clinical trials and future directions. Anticancer Agents Med Chem 8:86–91PubMedCrossRef Franco A (2008) Glycoconjugates as vaccines for cancer immunotherapy: clinical trials and future directions. Anticancer Agents Med Chem 8:86–91PubMedCrossRef
15.
go back to reference Krug LM, Ragupathi G, Hood C, Kris MG, Miller VA, Allen JR, Keding SJ, Danishefsky SJ, Gomez J, Tyson L, Pizzo B, Baez V, Livingston PO (2004) Vaccination of patients with small-cell lung cancer with synthetic fucosyl GM-1 conjugated to keyhole limpet hemocyanin. Clin Cancer Res 10:6094–6100PubMedCrossRef Krug LM, Ragupathi G, Hood C, Kris MG, Miller VA, Allen JR, Keding SJ, Danishefsky SJ, Gomez J, Tyson L, Pizzo B, Baez V, Livingston PO (2004) Vaccination of patients with small-cell lung cancer with synthetic fucosyl GM-1 conjugated to keyhole limpet hemocyanin. Clin Cancer Res 10:6094–6100PubMedCrossRef
16.
go back to reference Slovin SF, Ragupathi G, Musselli C, Olkiewicz K, Verbel D, Kuduk SD, Schwarz JB, Sames D, Danishefsky S, Livingston PO, Scher HI (2003) Fully synthetic carbohydrate-based vaccines in biochemically relapsed prostate cancer: clinical trial results with alpha-N-acetylgalactosamine-O-serine/threonine conjugate vaccine. J Clin Oncol 21:4292–4298PubMedCrossRef Slovin SF, Ragupathi G, Musselli C, Olkiewicz K, Verbel D, Kuduk SD, Schwarz JB, Sames D, Danishefsky S, Livingston PO, Scher HI (2003) Fully synthetic carbohydrate-based vaccines in biochemically relapsed prostate cancer: clinical trial results with alpha-N-acetylgalactosamine-O-serine/threonine conjugate vaccine. J Clin Oncol 21:4292–4298PubMedCrossRef
17.
go back to reference Pan YB, Chefalo P, Nagy N, Harding CV, Guo Z (2005) Synthesis and immunological properties of N-modified GM3 antigens as therapeutic cancer vaccines. J Med Chem 48:875–883PubMedCrossRef Pan YB, Chefalo P, Nagy N, Harding CV, Guo Z (2005) Synthesis and immunological properties of N-modified GM3 antigens as therapeutic cancer vaccines. J Med Chem 48:875–883PubMedCrossRef
18.
go back to reference Wu J, Guo Z (2006) Improving the antigenicity of sTn antigen by modification of its sialic acid residue for development of glycoconjugate cancer vaccines. Bioconjugate Chem 17:1537–1544CrossRef Wu J, Guo Z (2006) Improving the antigenicity of sTn antigen by modification of its sialic acid residue for development of glycoconjugate cancer vaccines. Bioconjugate Chem 17:1537–1544CrossRef
19.
go back to reference Wang Q, Zhang J, Guo Z (2007) Efficient glycoengineering of GM3 on melanoma cell and monoclonal antibody-mediated selective killing of the glycoengineered cancer cell. Bioorg Med Chem 15:7561–7567PubMedCrossRef Wang Q, Zhang J, Guo Z (2007) Efficient glycoengineering of GM3 on melanoma cell and monoclonal antibody-mediated selective killing of the glycoengineered cancer cell. Bioorg Med Chem 15:7561–7567PubMedCrossRef
20.
go back to reference Guo Z (2009) Glycoengineering of cell surface sialic acid and its application to cancer immunotherapy. In: Guo Z, Boons G-J (eds) Carbohydrate-based vaccines and immunotherapies. Hoboken, New Jersey, pp 313–331CrossRef Guo Z (2009) Glycoengineering of cell surface sialic acid and its application to cancer immunotherapy. In: Guo Z, Boons G-J (eds) Carbohydrate-based vaccines and immunotherapies. Hoboken, New Jersey, pp 313–331CrossRef
21.
go back to reference Chefalo P, Pan Y, Nagy N, Harding C, Guo Z (2006) Effective metabolic engineering of GM3 on tumor cells by N-phenylacetyl-d-mannosamine. Biochemistry 45:3733–3739PubMedCrossRef Chefalo P, Pan Y, Nagy N, Harding C, Guo Z (2006) Effective metabolic engineering of GM3 on tumor cells by N-phenylacetyl-d-mannosamine. Biochemistry 45:3733–3739PubMedCrossRef
22.
go back to reference Yu S, Wang Q, Zhang J, Wu Q, Guo Z (2011) Synthesis and evaluation of protein conjugates of GM3 derivatives carrying modified sialic acids as highly immunogenic cancer vaccine candidates, MedChemComm 2. doi:10.1039/c1031md00033k Yu S, Wang Q, Zhang J, Wu Q, Guo Z (2011) Synthesis and evaluation of protein conjugates of GM3 derivatives carrying modified sialic acids as highly immunogenic cancer vaccine candidates, MedChemComm 2. doi:10.​1039/​c1031md00033k
23.
go back to reference Wang Q, Guo Z (2011) Synthetic and immunological studies of sTn derivatives carrying substituted phenylacetylsialic acids as cancer vaccine candidates. ACS Med Chem Lett 2. doi:10.1021/ml100313d Wang Q, Guo Z (2011) Synthetic and immunological studies of sTn derivatives carrying substituted phenylacetylsialic acids as cancer vaccine candidates. ACS Med Chem Lett 2. doi:10.​1021/​ml100313d
24.
go back to reference Tsuchida T, Saxton RE, Morton DL, Irie RF (1987) Gangliosides of human melanoma. J Natl Cancer Inst 78:45–54PubMed Tsuchida T, Saxton RE, Morton DL, Irie RF (1987) Gangliosides of human melanoma. J Natl Cancer Inst 78:45–54PubMed
25.
go back to reference Hirabayashi Y, Hamaoka A, Matsumoto M, Matsubara T, Tagawa M, Wakabayashi S, Taniguchi M (1985) Syngeneic monoclonal antibody against melanoma antigen with interspecies cross-reactivity recognizes GM3, a prominent ganglioside of B16 melanoma. J Biol Chem 260:13328–13333PubMed Hirabayashi Y, Hamaoka A, Matsumoto M, Matsubara T, Tagawa M, Wakabayashi S, Taniguchi M (1985) Syngeneic monoclonal antibody against melanoma antigen with interspecies cross-reactivity recognizes GM3, a prominent ganglioside of B16 melanoma. J Biol Chem 260:13328–13333PubMed
26.
go back to reference Ollila DW, Kelley MC, Gammon G, Morton DL (1998) Overview of melanoma vaccines: active specific immunotherapy for melanoma patients. Semin Surg Oncol 14:328–336PubMedCrossRef Ollila DW, Kelley MC, Gammon G, Morton DL (1998) Overview of melanoma vaccines: active specific immunotherapy for melanoma patients. Semin Surg Oncol 14:328–336PubMedCrossRef
27.
28.
go back to reference Liu T, Guo Z, Yang Q, Sad S, Jennings HJ (2000) Biochemical engineering of surface α(2–8)polysialic acid for immunotargeting cancer cells. J Biol Chem 275:32832–32836PubMedCrossRef Liu T, Guo Z, Yang Q, Sad S, Jennings HJ (2000) Biochemical engineering of surface α(2–8)polysialic acid for immunotargeting cancer cells. J Biol Chem 275:32832–32836PubMedCrossRef
Metadata
Title
Combining synthetic carbohydrate vaccines with cancer cell glycoengineering for effective cancer immunotherapy
Authors
Lei Qiu
Xi Gong
Qianli Wang
Jie Li
Honggang Hu
Qiuye Wu
Junping Zhang
Zhongwu Guo
Publication date
01-11-2012
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 11/2012
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-012-1224-6

Other articles of this Issue 11/2012

Cancer Immunology, Immunotherapy 11/2012 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine